In 2026, a L’Oréal research team published clinical data showing a peptide serum reduced static wrinkles by up to sixty-nine percent in twelve weeks. The serum contained two neuropeptide inhibitors. One was acetyl hexapeptide-8 — widely known as Argireline. The other was a lesser-known molecule called dipeptide diaminobutyroyl benzylamide diacetate. Most people know it by its trade name: Syn-Ake. And it works through a mechanism that sounds like something out of a nature documentary.
Syn-Ake is a synthetic tripeptide designed to mimic a component of snake venom. It targets the same neuromuscular pathway that Botox does. But where Botox requires needles and a clinic visit, Syn-Ake works as a topical ingredient in a serum or cream. The question worth asking is simple. Does a snake-venom-inspired peptide actually relax expression lines when you put it on your skin? The science says yes — with some important caveats.
What Syn-Ake Actually Is
Syn-Ake is the trade name for dipeptide diaminobutyroyl benzylamide diacetate. It is a synthetic tripeptide developed by Pentapharm, a Swiss biotech company now owned by DSM. The peptide was designed by studying waglerin-1. Waglerin-1 is a twenty-two amino acid toxin found in the venom of the Wagler’s pit viper, a snake native to Southeast Asia. In nature, this toxin paralyzes prey by blocking nerve signals to muscles. Pentapharm’s insight was to isolate the active motif of waglerin-1 and turn it into a much smaller, stable, and safe synthetic peptide for cosmetic use.
The molecule is tiny compared to most cosmetic peptides. It has a molecular weight of roughly five hundred daltons. For reference, Argireline weighs about eight hundred ninety daltons and Matrixyl is over nine hundred. This small size matters for skin penetration. But we will get to that. What makes Syn-Ake fundamentally different from peptides like Matrixyl or GHK-Cu is its target. Most anti-aging peptides work by sending signals to fibroblasts — the cells that produce collagen and elastin. Syn-Ake does not talk to fibroblasts at all. It talks to muscle cells. And it tells them to stop contracting.
The Snake Venom Connection
Here is where the biology gets interesting. Your facial muscles contract because motor neurons release a chemical messenger called acetylcholine. Acetylcholine crosses the tiny gap between nerve and muscle — the neuromuscular junction — and docks onto nicotinic acetylcholine receptors on the muscle cell surface. This docking triggers a chain reaction of ion flow that makes the muscle fiber contract. Smile lines, crow’s feet, and forehead furrows all start right here.
Waglerin-1, the snake toxin, is a competitive antagonist of the muscle nicotinic acetylcholine receptor. In plain language: it jumps into the receptor’s docking site and physically blocks acetylcholine from binding. No acetylcholine binding means no muscle contraction. No contraction means no wrinkle formation. A landmark 1999 study in the Journal of Pharmacology and Experimental Therapeutics showed that waglerin-1 selectively blocks the epsilon subunit of the receptor. The epsilon subunit is the mature, adult form. This is why infant mice with immature receptors resist waglerin-1 but adult mice are paralyzed by it. The selectivity is precise.
Pentapharm’s chemists studied the three-dimensional structure of waglerin-1 and identified the specific amino acid sequence responsible for receptor blocking. They then synthesized a much simpler tripeptide that preserved the binding motif. The result was Syn-Ake. Unlike the full toxin — which is twenty-two amino acids long and too large to pass through skin — Syn-Ake is small enough for topical delivery. And unlike the real venom, it is non-toxic to mammals. In vitro safety studies published in 2024 confirmed the peptide had no cytotoxic or genotoxic effects at relevant concentrations.
How Syn-Ake Talks to Your Muscle Cells
Now here is the key data point. A 2024 study in the Journal of Biomolecular Structure and Dynamics mapped exactly how Syn-Ake interacts with its biological targets. The researchers used molecular docking simulations to test Syn-Ake against several matrix metalloproteinases — enzymes that break down collagen — and a longevity-associated protein called SIRT1. Syn-Ake bound to SIRT1 with a docking score of negative nine point three two kilocalories per mole. That is a strong, stable interaction. Molecular dynamics simulations over fifty nanoseconds confirmed the peptide stayed locked in the SIRT1 active site the entire time.
But the anti-wrinkle mechanism goes beyond enzyme binding. The primary mode of action is at the neuromuscular junction. Syn-Ake mimics the receptor-blocking motif of waglerin-1. It competes with acetylcholine for the nicotinic receptor’s binding pocket on the muscle cell. When Syn-Ake occupies that pocket, acetylcholine cannot land there. The ion channel stays closed. The muscle does not receive the signal to contract. The result is a measurable reduction in muscle contraction amplitude — which translates directly to softer, shallower expression lines on the skin surface.
Here is what experienced formulation chemists understand about this mechanism. The effect is concentration-dependent and reversible. Syn-Ake does not permanently paralyze the receptor. It competes dynamically with acetylcholine. As Syn-Ake molecules naturally degrade or diffuse away from the receptor site, acetylcholine regains access. This is fundamentally different from Botox. Botox enzymatically cleaves SNARE proteins inside the nerve terminal. The nerve cannot release acetylcholine at all until it grows new terminals — a process that takes three to four months. Syn-Ake wears off much faster. This is both a limitation and a safety advantage. You need to apply it daily. But you are never looking at months of frozen expression.
An additional finding from the 2024 study adds another dimension. Syn-Ake demonstrated concentration-dependent antioxidant activity in the DPPH radical scavenging assay. Free radicals contribute to skin aging by damaging collagen fibers and cellular DNA. So Syn-Ake appears to pull double duty. It relaxes expression muscles and scavenges oxidative damage. This dual mechanism helps explain why clinical studies show improvements not just in wrinkle depth but also in overall skin quality.
The SIRT1 interaction deserves its own mention. SIRT1 is a longevity-associated protein that regulates cellular stress responses and mitochondrial function. When SIRT1 is active, cells repair DNA damage more efficiently. They manage oxidative stress better. They produce more ATP — the energy currency of cells. The 2024 docking study found Syn-Ake bound to SIRT1 with stronger affinity than it bound to any of the three MMP enzymes tested. The fifty-nanosecond molecular dynamics simulation confirmed this binding was stable and persistent. Activating SIRT1 in skin cells is a well-validated anti-aging strategy. Resveratrol, a famously studied anti-aging compound, works partly through SIRT1 activation. So Syn-Ake is tapping into a pathway that the longevity research community has been studying for decades. The fact that a three-amino-acid peptide can activate this pathway while also blocking muscle acetylcholine receptors is remarkable. It is two anti-aging mechanisms packed into one very small molecule.
The Skin Barrier Problem
Peptides and skin have a difficult relationship. The stratum corneum — the outermost layer of your epidermis — is designed to keep things out. It is a densely packed layer of dead skin cells embedded in a lipid matrix. Most molecules larger than five hundred daltons struggle to cross it unassisted. Syn-Ake sits right at the threshold at roughly five hundred daltons. This gives it a theoretical advantage over larger peptide competitors. But theoretical advantage and practical performance are not the same thing.
A 2025 review in the journal BioImpacts examined the skin permeability challenges that all anti-wrinkle peptides face — including GHK-Cu and palmitoylated derivatives. The findings apply directly to Syn-Ake as well. Hydrophilic peptides dissolve well in water-based serums but partition poorly into the lipid-rich stratum corneum. This is the fundamental tension of topical peptide delivery. If a peptide is too water-loving it sits on the skin surface. If it is too fat-loving it gets trapped in the lipid layers and never reaches the living epidermis and dermis below.
The review highlighted a surprising gap in the cosmetic peptide literature. Despite the widespread use of GHK-Cu and Pal-GHK in anti-wrinkle products, published clinical studies on their skin permeability are scarce. Brands market these peptides aggressively. But the peer-reviewed data on how much actually crosses the stratum corneum is thin. The report noted that palmitoylation — attaching a fatty acid chain to the peptide — does improve permeability by making the molecule more lipophilic. But it is not a magic bullet. Palmitoylated peptides still face the lipid barrier. Chemical enhancers, cell-penetrating peptides, and physical methods like microneedling all improve the odds.
Encouragingly, new delivery technologies are changing the equation. A 2025 paper in Dermatologic Surgery described Tiered-Release Vesicles — a multilamellar delivery system that improved peptide penetration by two to five times compared to optimized liposomes in ex vivo human skin. These systems use concentric phospholipid bilayers that fuse with the stratum corneum’s own lipid matrix, creating temporary channels for peptide passage. The technology was originally demonstrated with large peptides and hyaluronic acid but the same principles apply to smaller peptides like Syn-Ake. When you see a Syn-Ake product on the shelf, the delivery system matters almost as much as the peptide concentration. A plain water-based serum with Syn-Ake at four percent may deliver less active peptide to the dermis than a liposomal formulation at two percent.
What the Clinical Data Shows
So does any of this actually work on real human faces? The strongest evidence comes from a 2026 study published in the International Journal of Cosmetic Science. L’Oréal researchers tested a serum containing Syn-Ake alongside acetyl hexapeptide-8, gluconolactone, niacinamide, and laminaria extract. The study included two clinical trials. The first measured static wrinkles — the lines visible even when your face is at rest. Fifty participants used the serum for twelve weeks. The numbers tell the story.
Static wrinkle clinical scores improved by thirty-five to sixty-nine percent depending on the wrinkle type. All results were statistically significant — p values below zero point zero zero one across the board. Dynamic wrinkles — the lines that appear with facial movement — improved by ten to thirteen percent. These are smaller numbers, but the mechanism makes sense here. Neuropeptide inhibitors reduce muscle contraction amplitude. They do not eliminate it entirely. A ten to thirteen percent reduction in wrinkle depth during expression is consistent with partial, reversible receptor blockade.
But here is what most people miss about these results. The serum showed multiple benefits beyond wrinkle reduction. Skin smoothness improved by thirty percent. Radiance went up twenty-seven percent. Pore appearance improved by forty-three percent. Elasticity increased thirty-three percent. Firmness improved thirty-six percent. Some of these effects come from the other ingredients in the formulation. Niacinamide is a well-established skin barrier enhancer. Gluconolactone is a gentle polyhydroxy acid that exfoliates. But the wrinkle improvements specifically align with what you would expect from a neuromuscular inhibitor. The ex vivo arm of the study supported this. Treated skin samples showed increased levels of collagen types one, three, four, and seventeen — along with higher elastic fiber content and reduced MMP-1 activity.
A separate 2024 study tested pure Syn-Ake peptide in vitro. The researchers measured its binding to SIRT1 and MMP enzymes, its antioxidant capacity, and its safety profile in both cytotoxicity and genotoxicity assays. The peptide passed all safety tests. It showed dose-dependent activity across all measured endpoints. This independent validation matters because the L’Oréal study used a multi-ingredient serum. You cannot attribute all benefits to Syn-Ake alone when you are testing a cocktail. The in vitro study isolates the peptide and confirms it has real biological activity.
What Experienced Teams Know
Here is the anti-pattern that catches formulators. Syn-Ake is a water-soluble peptide with a relatively short serum half-life once applied to skin. Most brands put it in a water-based serum at concentrations between one and four percent and call it a day. That approach delivers the peptide to the skin surface. But how much actually reaches the neuromuscular junction? The honest answer is: not as much as the in vitro data would suggest. This is the gap between a petri dish and a human face.
The second pitfall is the concentration race. Some brands advertise Syn-Ake at eight or ten percent, implying that higher concentration equals better results. The receptor biology does not support this logic. Syn-Ake competes with acetylcholine at the binding site. Once you have enough peptide to saturate available receptors — a threshold that depends on formulation, not just raw percentage — adding more does nothing. It is like putting ten keys in a lock that only accepts one. The extra keys just sit there. What matters more than absolute concentration is the delivery system. Does the peptide actually reach the dermal-epidermal junction in an active form? That depends on the vehicle, not the label percentage.
A third reality check concerns the timeline. Clinical studies run twelve weeks because that is how long it takes to see the full effect on static wrinkles. If you use a Syn-Ake serum for two weeks and give up because you do not look ten years younger, you have not given the mechanism enough time. The peptide needs to accumulate in the tissue, reach the neuromuscular junction, and then the skin needs time to remodel around the reduced muscle tension. This is not a next-day result. The L’Oréal study noted visible improvements starting in week one, but the magnitude was modest. The sixty-nine percent figure happens at twelve weeks.
Where Syn-Ake Fits in Your Routine
Syn-Ake plays well with others. You can layer it with signal peptides like Matrixyl. The two mechanisms do not compete. Signal peptides tell fibroblasts to make more collagen. Syn-Ake tells muscles to relax. These are complementary strategies for different aspects of skin aging. You can also pair Syn-Ake with copper peptides like GHK-Cu, though you should apply them at different times of day if both are in water-based serums. Copper can catalyze oxidation reactions that degrade other peptides if they share a vehicle for too long.
What about comparing Syn-Ake directly to Argireline? Both are neurotransmitter inhibitors. Both target expression lines. But their mechanisms differ significantly. Argireline mimics the SNAP-25 protein fragment that Botox normally cleaves. It interferes with the SNARE complex assembly inside the nerve terminal. This blocks vesicle fusion — the final step where acetylcholine is released into the synapse. Syn-Ake takes the opposite approach. It does not block release. It blocks reception. It sits on the muscle side of the synapse and prevents acetylcholine from binding. Some dermatologists suggest using both together for a more complete neuromuscular blockade. The logic is solid on paper. But clinical head-to-head data comparing the two is limited.
One final thought on product selection. Look for serums that disclose their Syn-Ake concentration — ideally between two and four percent — and pair the peptide with a penetration-enhancing delivery system. Liposomal encapsulation, microemulsions, or the newer TRV technology all improve the odds that the peptide actually gets where it needs to go. A product that simply lists dipeptide diaminobutyroyl benzylamide diacetate somewhere in the middle of an INCI list without specifying delivery technology is probably not optimized for performance.
Further Reading
- Argireline vs. Syn-Ake: How Neuropeptide Inhibitors Compare
- Signal Peptides Explained: How Matrixyl Boosts Collagen
- Why Your Peptide Serum Might Not Be Working: A Formulation Deep Dive
Last reviewed: July 2026. Peptide Proof Editorial Team.
Sources
Zhu M, He X, Zhu Z, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture. International Journal of Cosmetic Science. 2026. DOI: 10.1111/ics.70087.
Gok B, Budama-Kilinc Y, Kecel-Gunduz S. Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. Journal of Biomolecular Structure and Dynamics. 2024 volume 42 issue 10 pages 5015 to 5029.
McArdle JJ, Lentz TL, Witzemann V, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. Journal of Pharmacology and Experimental Therapeutics. 1999 volume 289 issue 1 pages 543 to 550.
Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025 volume 15 article 30071.
Moradi A, Bhatia AC, Behr K, Napekoski K, Foldvari M. In vivo and ex vivo evaluation of a novel method for topical delivery of macromolecules through the stratum corneum for cosmetic applications. Dermatologic Surgery. 2025 volume 51 issue 4 pages 403 to 408.
